hiv cure: “shock & kill” in siv macaque model ... · hiv cure: “shock & kill” in...
TRANSCRIPT
Janice E. Clement, Lucio Gama
The Retrovirus Laboratory
NeuroHIV 2015, Matera, Italy
October 10, 2015
HIV CURE: “Shock & Kill” in SIV Macaque Model: Reactivation of Virus in CSF & Plasma
SIV Macaque Model of AIDS & CNS Disease
Innate Immune & Cytokine Changes – Acute Infection Brain
cART Reduces Virus Replication & CNS DiseaseViral DNA in Brain and Tissues
Zink et al., JID, 2010
Tenofovir / Saquinavir / Atazanavir / Merck L-870812
Latently Infected SIV Resting CD4+ T Cells by QVOA
Dinoso et al., JV, 2009
Plasma Tissues
QVOA parallels HIV quantitative viral outgrowth assay
Zink et al., JID, 2010
Viral RNA Viral DNA
Residual Viral RNA (<30 copies/ug RNA)NO difference in viral DNA
Bra
in S
IV R
NA
(lo
g10
co
py
eq./
ug
RN
A
In situ RNA Hybridization in Brain
HAART Reduces Virus Replication & CNS Disease –Viral DNA Reservoir Persists
Deeks. S., Nature - 2012
cART+ Shock Kill No ViralSpread
Ingenol derivatives activate latent HIVin cell lines & resting CD4+ T cells from ART suppressed patients
Ingenol-B Reactivates HIV & SIV in resting CD4+ T cells
Siliciano Lab Van Lint Lab
Clements Lab
0 200 400 60010-1
101
103
105
107
109
days p.i.
SIV
RN
A c
op
y e
q/m
LPlasma Viral Load
Spleen biopsy Spleen biopsy
+ Ing-B
Ingenol-B oral dose 0.4mg/kg daily 45 d
Ingenol-B oral dose 0.6mg/kg daily 12 dVorinostat 6 mg/kg 4 doses 12 d
Long-term cART Suppressed SIV Macaques Shock – Ingenol-B & Vorinostat
Untreated
Ingenol-B + Vorinostat
Plasma Virus Load – Ingenol-B & Vorinostat
Untreated
Ingenol-B + Vorinostat
Activation of CD69 on CD4+ & CD8+ Lymphocytes
No increase in cytokines in plasma: consistent with NO “cytokine storm”as in acute HIV/SIV infection
Activation of CD69 CD4+ & CD8+ Lymph Nodes & Spleen
Decrease in Resting CD4+ T cell Reservoir
CSF Virus– Ingenol-B & Vorinostat
Untreated
Ingenol-B + Vorinostat
Increased CCL2, Neopterin & NFL in CSF
RNA was quantified by dd-PCR and normalized to the ug of RNA used in the assay.
SIV RNA in Tissues from Ingenol-B Vorinostat Treated Macaques
• SIV-infected macaques treated suppressed with long-term ART >6 months.• Release of macaques from ART, resulted in reactivation of SIV in plasma
PT3 at 4d plasma virus 216 copies of SIV RNA/ml; CSF virus 168 copies of SIV RNA/ml.
PT4 at 5 d plasma virus 225 copies of SIV RNA/ml; CSF virus <10 copies of SIV RNA/ml.
Reactivation of SIV in Suppressed Macaques Removed ART
S. Weitgrefe & A. Haase
In Situ Hybridization of Brain
165 RNA copies/ml CSF
Phylogenetic Analyses of Env V1 Region in Pt2Virus in Plasma & CSF – DNA in Brain and Peripheral Tissues
Phylogenetic Analyses of Env V1 Region in Pt3 & P4Virus in Plasma & CSF – DNA PBMC
Conclusions
• SIV Macaque experiments provided proof-of-concept for “Shock & Kill”:• Shock: There was increase in viral load – both plasma & CSF• Kill: There was decay of latently-infected resting CD4+ T cells
in blood
• A combination of Latency Reversing Agents reactivated SIV in plasma and CSF in macaques suppressed for >500 days:• In situ hybridization detection of SIV in brain.• Cytokine increase in CSF and not plasma• Increase in NFL in CSF • Increased expression of CD69 on CD4+ and CD8+ T cells in blood.• NO Cytokine storm in plasma
• Reactivation in brain accompanied by CNS symptoms – caveat for CURE?
Collaborators
U19 AI 096113
Johns Hopkins SOM
Lucio Gama
Joseph Mankowski
Kelly Pate
M. Christine Zink
Robert Adams
Robert Siliciano
Gregory Laird
Kai Deng
Janet SilicianoIndustry Support
Merck
Gilead
Bristol-Myers Squibb
NIH Support
NIMHNINDS NIAID
University of Rio de Janiero
Luis Pianowski
University of Wisconsin
Shelby O’ Connor
University of Minnesota
Ashley Haase
Steve Weitgrefe
Is Latency & Reactivation of HIV in Macrophages a Deterrent to HIV CURE?
• Currently, human trials with CURE therapeutic approaches examine only plasma for HIV reactivation. CSF should also be tested for virus or plasma examined for CNS Biomarkers of activation – NFL, sCD163?
• Research on HIV latency and reactivation should include cells of myeloid lineage, multiple tissue macrophages – brain, spleen, liver...
• In vitro models used to screen drugs candidates should includehuman macrophage that accurately mirror a variety of tissue macrophages.
• HIV CURE therapy may need to include neuroprotective/anti-inflammatory agents to protect brain & other tissues from virus reactivation in CD4+ T cells and myeloid cells.